Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | GHSR | Q92847 | 4/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074609 | 1.00 | CYP2D6 (0.47) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL3079424 | 1.00 | CYP2D6 (0.47) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL3075921 | 0.94 | CYP2D6 (0.44) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL3075920 | 0.94 | CYP2D6 (0.44) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL14781471 | 0.92 | CYP2D6 (0.43) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL3068382 | 0.90 | MEN1 (0.46) | CYP2D6GHSRS1PR1POLBMEN1 | |
| SCHEMBL3080112 | 0.90 | CYP2D6 (0.48) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL3080117 | 0.90 | CYP2D6 (0.48) | CYP2D6GHSRS1PR1GAAHTT | |
| SCHEMBL3068385 | 0.90 | MEN1 (0.46) | CYP2D6GHSRS1PR1POLBMEN1 | |
| SCHEMBL3071289 | 0.89 | GHSR (0.46) | CYP2D6GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | CYP2D6 1127/4885GHSR 351/4885S1PR1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.